Showing results (181-190 of 401) with videos related to
Sort By:
Pageof 41
American Heart Journal|May 27, 2003
Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of lifeDavid M Newman, Paul Dorian, Miney Paquette, et al.The Canadian Journal of Cardiology|June 2, 2012
The burden of atrial fibrillation on the hospital sector in CanadaDaria J O'Reilly, Robert B Hopkins, Jeff S Healey, et al.Resuscitation|March 19, 2026
The impact of defibrillation current and pad position on return of spontaneous circulation during refractory ventricular fibrillationSheldon Cheskes, Ian R Drennan, Linda Turner, et al.European Heart Journal|September 29, 2012
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapyMichiel Coppens, John W Eikelboom, Robert G Hart, et al.Journal of Cardiovascular Electrophysiology|September 9, 2008
Influence of ventriculoatrial timing on hemodynamics and symptoms during supraventricular tachycardiaGabriel Laurent, Howard Leong-Poi, Iqwal Mangat, et al.Clinical Therapeutics|February 11, 2014
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillationGregory Y H Lip, Thitima Kongnakorn, Hemant Phatak, et al.Resuscitation|February 19, 2020
High risk neighbourhoods: The effect of neighbourhood level factors on cardiac arrest incidenceKatherine S Allan, Joel G Ray, Peter Gozdyra, et al.Journal of the American Heart Association|April 25, 2015
Identifying predictors of cumulative healthcare costs in incident atrial fibrillation: a population-based studyMaria C Bennell, Feng Qiu, Andrew Micieli, et al.The Canadian Journal of Cardiology|June 15, 2005
Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in CanadaAnthony S Tang, Heather Ross, Christopher S Simpson, et al.Journal of Cardiovascular Pharmacology|April 24, 2013
Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillatorDongsheng Gao, Hugo Van Herendael, Lamia Alshengeiti, et al.Pageof 41